Coverage by Drug Topics as tracked by Newsylist.
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
5 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
5 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
10 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.